Abstract
The occurrence of schistosomiasis within African infants and preschool children has been much better documented in recent years, revealing an important burden of disease previously overlooked. Despite mounting evidence showing that treatment with praziquantel is safe, beneficial, and could be delivered within ongoing public health interventions, young children still do not have satisfactory access to this drug, and a significant treatment gap exists. Progress towards resolution of this unfortunate health inequity is highlighted, including the development of an appropriate paediatric praziquantel formulation, and present blocks are identified on securing this issue within the international health agenda.
| Original language | English |
|---|---|
| Pages (from-to) | 197-205 |
| Number of pages | 9 |
| Journal | Trends In Parasitology |
| Volume | 29 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 5 Mar 2013 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cure rates
- HIV
- Malaria
- Neglected tropical diseases
- Paediatrics
- Pharmacokinetics
- Praziquantel
- Preventive chemotherapy
Fingerprint
Dive into the research topics of 'Schistosomiasis in African infants and preschool children: let them now be treated!'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver